Biotechnology

Lipid nanoparticles build CAR NK cells inside the body, skipping manufacturing

MIT researchers report that targeted lipid nanoparticles reprogrammed up to 80 per cent of natural killer cells in mice, clearing tumours and autoreactive T cells without ex vivo cell manufacturing.

Anam · Oct 29, 2026 · 8 min read

Neuroscience

Solengepras cuts Parkinson's OFF time in phase 3 without targeting dopamine

A once-daily GPR6 inhibitor reduced daily OFF time by 0.61 hours versus placebo in the ARISE trial, a phase 3 win for a non-dopaminergic approach to Parkinson's.

Anam · Oct 28, 2026 · 9 min read

Drug Discovery

AI-Designed TEAD Inhibitor ISM6331 Reports First-in-Human Data in Mesothelioma

Insilico's generative-chemistry pan-TEAD inhibitor shrank tumours in a few heavily pretreated mesothelioma patients at ESMO 2026. Here is what the small, company-reported dataset does and does not show.

Anam · Oct 26, 2026 · 8 min read

Oncology

Personalized mRNA Neoantigen Therapy Cuts Melanoma Recurrence in Phase 3

In INTerpath-001, intismeran plus pembrolizumab lowered the risk of recurrence or death by 42% in resected melanoma, with the benefit emerging only after vaccination ended.

Anam · Oct 24, 2026 · 8 min read

Genomics & Genetics

Atlas of 10 Million Immune Cells Traces How Disease Variants Reach Genes

Paired chromatin and RNA profiling of blood cells from 1,108 Finnish donors links non-coding variants to specific genes and explains why constrained genes hide their eQTLs.

Anam · Oct 23, 2026 · 8 min read

Research & Development

Ono Licenses Biohaven's IgG Degraders: What the MoDE Platform Does

An $80 million upfront deal brings a new way of clearing autoantibodies to Asia. Here is how the liver-directed degraders work and what the early Graves' disease data do and do not show.

Anam · Oct 22, 2026 · 8 min read

Regulatory Affairs

FDA Expedited IND Pilot Tests Rolling Review for First-in-Human Trials

Applications close 30 October for an FDA pilot that reviews first-in-human IND sections as they are finished, with sponsors paired with outside research institutions.

Anam · Oct 22, 2026 · 9 min read

Medical Devices

FDA Approves Hydrogel Spacer to Curb Scarring After Uterine Adhesion Surgery

Juveena, a gel that sets inside the uterus and clears in two to three weeks, cut adhesion recurrence in a blinded trial. Key figures come from a subgroup and await publication.

Anam · Oct 21, 2026 · 8 min read

Digital Health

Conversational AI Takes Histories Before Real Primary Care Visits

In a Lancet feasibility study at Beth Israel Deaconess, Google's AMIE chatted with 98 urgent care patients before their visits without a single safety stop. It had no control arm and a physician watched every chat.

Anam · Oct 20, 2026 · 8 min read

Clinical Trials

Retatrutide Explained: Trial Results, FDA Filing and the Counterfeit Risk

Lilly's triple agonist has won four phase 3 trials and is due for US filing in early 2027. Until then, anything sold online as retatrutide is unapproved and of unknown quality.

Anam · Oct 19, 2026 · 8 min read

Biotechnology

Base Editing Gives First Clinical Signal in Glycogen Storage Disease Type Ia

Six patients treated with Beam's BEAM-301 needed less cornstarch and fasted longer, but follow-up is short and the lower-dose effect waned.

Anam · Oct 19, 2026 · 9 min read

Drug Discovery

A Synthetic Lethal Drug Reaches Patients Seven Years After Its Target Was Found

The first WRN helicase inhibitor tested in humans held disease stable in three quarters of patients with microsatellite instability tumours, but shrank only one in ten.

Anam · Oct 18, 2026 · 7 min read